An anticipated Phase III trial of Riquent in lupus, meant to confirm data trends seen in a Phase II/III trial, brought about a similar result - good data trends but a missed primary endpoint, sending La Jolla Pharmaceutical Co.'s stock down 72.5 percent. (BioWorld Today)
An anticipated Phase III trial of Riquent in lupus, meant to confirm data trends seen in a Phase II/III trial, brought about a similar result - good data trends but a missed primary endpoint, sending La Jolla Pharmaceutical Co.'s stock down 72.5 percent. (BioWorld Today)
The necessary relationship between biotechnology companies and big pharma drives both industries - pharma has the money but often has science needs; biotechnology has the science but often lacks financial resources. (BioWorld Financial Watch)
The necessary relationship between biotechnology companies and big pharma drives both industries - pharma has the money but often has science needs; biotechnology has the science but often lacks financial resources. (BioWorld Financial Watch)
VANCOUVER - Dating advice often counsels that the best way to get a date is to ask for one. The same could be said for biotechnology companies seeking pharmaceutical partnerships. It's possible that big pharma will get wind of a young company's science, approach and begin the partnering dance, but making the first move for biotechnology companies and being proactive can't hurt. (BioWorld Today)
